Christina Bachmeier

7PUBLICATIONS
72CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma.

Khushali Jhaveri, Ram Thapa, Dalia Ercan

|Jan 09, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.

Rawan G Faramand, Sae Bom Lee, Michael D Jain

|Sep 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.

Kai Rejeski, Ariel Perez, Gloria Iacoboni

|Jun 12, 2023
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.

Dae Hyun Lee, Abhishek Kumar, Turab Mohammed

|Jan 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma.

Michael D Jain, Hua Zhao, Xuefeng Wang

|Jul 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel.

Rawan Faramand, Michael Jain, Verena Staedtke

Pageof 2

Frequent Collaborators

7 joint publications

Michael Jain

6 joint publications

Marco L Davila

5 joint publications

Aleksandr Lazaryan

5 joint publications

Taiga Nishihori